Individualized Cost-Effectiveness Analysis

John Ioannidis and Alan Garber discuss how to use incremental cost-effectiveness ratios (ICER) and related metrics so they can be useful for decision-making at the individual level, whether used by clinicians or individual patients.

[1]  Erry,et al.  Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. , 1995, The New England journal of medicine.

[2]  Joshua P Cohen,et al.  Switching prescription drugs to over the counter , 2004, BMJ : British Medical Journal.

[3]  Michael Doherty,et al.  Lifestyle interventions for knee pain in overweight and obese adults aged ≥45: economic evaluation of randomised controlled trial , 2009, BMJ : British Medical Journal.

[4]  John Cairns,et al.  Evaluation of modernisation of adult critical care services in England: time series and cost effectiveness analysis , 2009, BMJ : British Medical Journal.

[5]  A. Mehrez,et al.  Economics, health and health economics: HYEs versus QALYs , 1993 .

[6]  J. Lau,et al.  The impact of high-risk patients on the results of clinical trials. , 1997, Journal of clinical epidemiology.

[7]  M Meisner,et al.  Statistical inference for cost-effectiveness ratios. , 1997, Health economics.

[8]  Stephen W. Sorensen,et al.  The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance , 2005, Annals of Internal Medicine.

[9]  Richard L Kravitz,et al.  Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. , 2004, The Milbank quarterly.

[10]  M. Sculpher,et al.  Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease: cost effectiveness study , 2009, BMJ : British Medical Journal.

[11]  Douglas K. Owens,et al.  A Method for Estimating the Cost- Effectiveness of Incorporating Patient Preferences into Practice Guidelines , 1994, Medical decision making : an international journal of the Society for Medical Decision Making.

[12]  B. Gage,et al.  Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation , 2009, Annals of Internal Medicine.

[13]  C. Dewa,et al.  Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health Interventions , 2012, PharmacoEconomics.

[14]  B. Gage,et al.  Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. , 1998, Stroke.

[15]  A. Willan On the probability of cost-effectiveness using data from randomized clinical trials , 2001, BMC medical research methodology.

[16]  S. Goldie,et al.  Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States , 2009, BMJ : British Medical Journal.

[17]  Kilkon Ko,et al.  Procuring Organ Donors as a Health Investment: How Much Should We Be Willing to Spend? , 2004, Transplantation.

[18]  Martina Garau,et al.  Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study , 2004, BMJ : British Medical Journal.

[19]  David M Kent,et al.  Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal , 2010, Trials.

[20]  Kirsten Bibbins-Domingo,et al.  Comparing Impact and Cost-Effectiveness of Primary Prevention Strategies for Lipid-Lowering , 2009, Annals of Internal Medicine.

[21]  M. Gold Cost-effectiveness in health and medicine , 2016 .

[22]  R. Luce Utility of Gains and Losses: Measurement-Theoretical and Experimental Approaches , 2000 .

[23]  M. Mclaughlin Healthcare policy implications of heterogeneity of treatment effects. , 2007, The American journal of medicine.

[24]  A. Mehrez,et al.  Quality-adjusted Life Years, Utility Theory, and Healthy-years Equivalents , 1989, Medical decision making : an international journal of the Society for Medical Decision Making.

[25]  Anthony O'Hagan,et al.  The probability of cost-effectiveness , 2002, BMC medical research methodology.

[26]  R. Kravitz,et al.  Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment. , 2007, The American journal of medicine.

[27]  Les M Irwig,et al.  An evidence based approach to individualising treatment , 1995, BMJ.

[28]  D. Owens,et al.  Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. , 2009 .

[29]  S. Gilbody,et al.  Benefits and harms of direct to consumer advertising: a systematic review , 2005, Quality and Safety in Health Care.

[30]  N. Latimer,et al.  Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis , 2009, BMJ : British Medical Journal.

[31]  Douglas K Owens,et al.  High-Value, Cost-Conscious Health Care: Concepts for Clinicians to Evaluate the Benefits, Harms, and Costs of Medical Interventions , 2011, Annals of Internal Medicine.

[32]  S. Palmer,et al.  Screening for postnatal depression in primary care: cost effectiveness analysis , 2009, BMJ : British Medical Journal.

[33]  E. Elbasha Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach. , 2005, Health economics.

[34]  Dan Greenberg,et al.  Bias in published cost effectiveness studies: systematic review , 2006, BMJ : British Medical Journal.

[35]  J. Ioannidis,et al.  Industry involvement and baseline assumptions of cost-effectiveness analyses: diagnostic accuracy of the Papanicolaou test , 2011, Canadian Medical Association Journal.

[36]  A. Briggs,et al.  Trying to do better than average: a commentary on 'statistical inference for cost-effectiveness ratios'. , 1997, Health Economics.

[37]  B. O'brien,et al.  Building uncertainty into cost-effectiveness rankings: portfolio risk-return tradeoffs and implications for decision rules. , 2000, Medical care.

[38]  B. Watts,et al.  Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis , 2009, BMJ : British Medical Journal.

[39]  A. Mehrez,et al.  Economics, health and health economics: HYEs (healthy-years equivalent) versus QALYs (quality-adjusted live-year) , 1993, Journal of health economics.

[40]  M. Liang,et al.  Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents , 2009, Annals of Internal Medicine.

[41]  Caroline F Wright,et al.  Regulating direct-to-consumer genetic tests: What is all the fuss about? , 2011, Genetics in Medicine.

[42]  William D. Schafer,et al.  Gender differences in risk taking: A meta-analysis. , 1999 .

[43]  Paola Sapienza,et al.  Gender differences in financial risk aversion and career choices are affected by testosterone , 2009, Proceedings of the National Academy of Sciences.